PMID- 36281060
OWN - NLM
STAT- MEDLINE
DCOM- 20230222
LR  - 20230222
IS  - 1099-1573 (Electronic)
IS  - 0951-418X (Linking)
VI  - 37
IP  - 2
DP  - 2023 Feb
TI  - Juglone promotes antitumor activity against prostate cancer via suppressing 
      glycolysis and oxidative phosphorylation.
PG  - 515-526
LID - 10.1002/ptr.7631 [doi]
AB  - The treatments currently used for prostate cancer (PC) do not meet clinical 
      needs, and thus, new therapies with greater effectiveness are urgently required. 
      Metabolic reprogramming of tumor cells is emerging as an exciting field for 
      cancer therapy. Although the Warburg effect is a common feature of glucose 
      metabolism in many cancers, PC cells have a unique metabolic phenotype. 
      Non-neoplastic prostate cells show reduced oxidative phosphorylation (OXPHOS) 
      because large, accumulated zinc inhibits citrate oxidation. During 
      transformation, there are low levels of zinc in PC cells, and the tricarboxylic 
      acid (TCA) cycle is reactivated. However, metastatic PC exhibits the Warburg 
      effect. Due to metabolic differences in prostate tissue, targeting metabolic 
      alterations in PC cells is an attractive therapeutic strategy. In this study, we 
      investigated the effect of juglone on energy metabolism in PC cells. We found 
      that juglone inhibited cell proliferation and induced apoptosis. Mechanistically, 
      we demonstrated that juglone suppressed OXPHOS and glycolysis due to its 
      inhibition of hexokinase (HK), phosphofructokinase (PFK), and pyruvate kinase 
      (PK) activity. Furthermore, downregulation of PFK and PK, but not HK contributed 
      to the inhibition of these enzyme activities. The current study indicates that 
      further development of juglone for PC treatment would be beneficial.
CI  - (c) 2022 John Wiley & Sons Ltd.
FAU - Hu, Cheng
AU  - Hu C
AUID- ORCID: 0000-0003-3365-5225
AD  - College of Laboratory Medicine, Jilin Medical University, Jilin City, Jilin, 
      People's Republic of China.
FAU - Xu, Haiyue
AU  - Xu H
AD  - Clinical Laboratory Department, Changchun Obstetrics and Gynecology Hospital, 
      Changchun city, Jilin, People's Republic of China.
FAU - Li, Zehao
AU  - Li Z
AD  - College of Laboratory Medicine, Jilin Medical University, Jilin City, Jilin, 
      People's Republic of China.
FAU - Liu, Dandan
AU  - Liu D
AD  - College of Laboratory Medicine, Jilin Medical University, Jilin City, Jilin, 
      People's Republic of China.
FAU - Zhang, Siqi
AU  - Zhang S
AD  - College of medical technology, Beihua university, Jilin City, Jilin, People's 
      Republic of China.
FAU - Fang, Fang
AU  - Fang F
AUID- ORCID: 0000-0003-0352-7847
AD  - College of Laboratory Medicine, Jilin Medical University, Jilin City, Jilin, 
      People's Republic of China.
FAU - Wang, Liguo
AU  - Wang L
AUID- ORCID: 0000-0003-4620-8838
AD  - Department of Urology Surgery, Affiliated Hospital of Jilin Medical University, 
      Jilin City, Jilin, People's Republic of China.
LA  - eng
GR  - 201913706006/Jilin Provincial Training Programs of Innovation and 
      Entrepreneurship for Undergraduates/
GR  - 202013706067/Jilin Provincial Training Programs of Innovation and 
      Entrepreneurship for Undergraduates/
GR  - JJKH20210491KJ/Science and technology research project of the Jilin Provincial 
      Department of Education/
GR  - 2020J076/hygiene and health technology innovation project of the People's 
      Government of Jilin Province/
GR  - 2020J073/hygiene and health technology innovation project of the People's 
      Government of Jilin Province/
GR  - JJKH20200460KJ/science and technology project of the 13th five year plan of the 
      Jilin Provincial Department of Education/
PT  - Journal Article
DEP - 20221024
PL  - England
TA  - Phytother Res
JT  - Phytotherapy research : PTR
JID - 8904486
RN  - W6Q80SK9L6 (juglone)
RN  - EC 2.7.1.1 (Hexokinase)
SB  - IM
MH  - Humans
MH  - Male
MH  - *Oxidative Phosphorylation
MH  - Glycolysis/physiology
MH  - Energy Metabolism
MH  - *Prostatic Neoplasms/drug therapy
MH  - Hexokinase/metabolism
MH  - Cell Line, Tumor
OTO - NOTNLM
OT  - Warburg effect
OT  - glycolysis
OT  - juglone
OT  - metabolomics
OT  - oxidative phosphorylation
OT  - prostate cancer
EDAT- 2022/10/26 06:00
MHDA- 2023/02/22 06:00
CRDT- 2022/10/25 00:52
PHST- 2022/08/11 00:00 [revised]
PHST- 2022/03/17 00:00 [received]
PHST- 2022/09/03 00:00 [accepted]
PHST- 2022/10/26 06:00 [pubmed]
PHST- 2023/02/22 06:00 [medline]
PHST- 2022/10/25 00:52 [entrez]
AID - 10.1002/ptr.7631 [doi]
PST - ppublish
SO  - Phytother Res. 2023 Feb;37(2):515-526. doi: 10.1002/ptr.7631. Epub 2022 Oct 24.